Browsing: Medication & Drugs

CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based immunotherapies for the treatment of various cancers, announces today that it signed a Memorandum of Understanding (MOU) with Hangzhou CNK Therapeutics Co., Ltd (CNK).

Log In or Register as a healthcare professional to read the full article.

A revolutionary discovery by researchers in Singapore and MIT has uncovered a new bacterial stress signalling system, opening doors to new methods of combatting antibiotic resistance, a growing public health concern. The research team identified an enzyme, RlmN, that rapidly signals for the production of proteins allowing bacteria to adapt and survive. This could help design drugs that prevent this survival response, effectively tackling antibiotic resistance.